These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 10965095

  • 1. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
    Esposito S, Noviello S, Ianniello F.
    Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I, Robbins M, Viljoen L, Brown DF.
    J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y.
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [Abstract] [Full Text] [Related]

  • 5. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
    Lopez H, Vilches V, Scarano S, Stepanik D, Smayevsky J, Lemme L, Cardeñosa O, Ambler J, Sucari A.
    Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
    [Abstract] [Full Text] [Related]

  • 6. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
    Richard MP, Aguado AG, Mattina R, Marre R.
    J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
    [Abstract] [Full Text] [Related]

  • 7. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H, Liu YL, Chen MJ, Xu YC, Sun HL, Yang QW, Hu YJ, Cao B, Chu YZ, Liu Y, Zhang R, Yu YS, Sun ZY, Zhuo C, Ni YX, Hu BJ.
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [Abstract] [Full Text] [Related]

  • 8. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
    Wise R, Andrews JM.
    J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
    [Abstract] [Full Text] [Related]

  • 9. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
    Prado V, Giangrieco M, Durán C, Ojeda A, van Flaskamp R.
    Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of fluoroquinolones against common respiratory pathogens.
    Aydemir S, Tunger A, Cilli F.
    West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
    Koeth LM, Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Appelbaum PC.
    Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765
    [Abstract] [Full Text] [Related]

  • 12. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.
    Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF.
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).
    Deshpande LM, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):139-42. PubMed ID: 10863108
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
    Loza E, Morosini M, Negri MC, Almaraz F, Cantón R, Baquero F.
    Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023
    [Abstract] [Full Text] [Related]

  • 16. The activity of grepafloxacin against respiratory pathogens in the UK.
    Wise R, Andrews JM.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
    [Abstract] [Full Text] [Related]

  • 17. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, Alexander Project Group.
    J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
    [Abstract] [Full Text] [Related]

  • 18. [In vitro activity of moxifloxacin against respiratory pathogens in Latin America].
    López H, Sader H, Amábile C, Pedreira W, Muñoz Bellido JL, García Rodríguez JA, Grupo MSP-LA.
    Rev Esp Quimioter; 2002 Dec; 15(4):325-34. PubMed ID: 12587037
    [Abstract] [Full Text] [Related]

  • 19. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM, Suter M, Borsos S.
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [Abstract] [Full Text] [Related]

  • 20. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.